PAP
AVTX icon

Persistent Asset Partners’s Avalo Therapeutics AVTX Stock Holding History

Persistent Asset Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454K Buy
24,544
+16,626
+210% +$263K 0.14% 122
2026
Q1 		$118K Sell
7,918
-7,169
-48% -$112K 0.04% 231
2025
Q4 		$274K Buy
+15,087
New +$255K 0.12% 190

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Persistent Asset Partners's AVTX Position: Q2 2026 in Review

Persistent Asset Partners increased its Avalo Therapeutics (AVTX) stake by 210% in Q2 2026, buying an estimated $263K and bringing the position to 24,544 shares worth $454K. The position accounts for 0.14% of the portfolio, ranked #122.

Persistent Asset Partners first reported a position in AVTX in Q4 2025 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Persistent Asset Partners held 24,544 shares of Avalo Therapeutics worth $454K as of Q2 2026.
  • Persistent Asset Partners bought 16,626 Avalo Therapeutics shares in Q2 2026, an estimated $263K.
  • Avalo Therapeutics made up 0.14% of Persistent Asset Partners's portfolio in Q2 2026, its #122 holding.
  • Persistent Asset Partners first reported a position in Avalo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.